Literature DB >> 30115692

In Vivo Estimation of Oncolytic Virus Populations within Tumors.

Mi-Yeon Jung1, Chetan P Offord1, Matthew K Ennis1, Iris Kemler1, Claudia Neuhauser2,3, David Dingli4,3,5.   

Abstract

The use of replication-competent viruses as oncolytic agents is rapidly expanding, with several oncolytic viruses approved for cancer therapy. As responses to therapy are highly variable, understanding the dynamics of therapy is critical for optimal application of virotherapy in practice. Although mathematical models have been developed to understand the dynamics of tumor virotherapy, a scarcity of in vivo data has made difficult parametrization of these models. To tackle this problem, we studied the in vitro and in vivo spread of two oncolytic measles viruses that induce expression of the sodium iodide symporter (NIS) in cells. NIS expression enabled infected cells to concentrate radioactive isotopes that could be reproducibly and quantitatively imaged using SPECT/CT. We observed a strong linear relationship in vitro between infectious virus particles, viral N and NIS gene expression, and radioactive isotope uptake. In vivo radioisotope uptake was highly correlated with viral N and NIS gene expression. Similar expression patterns between viral N and NIS gene expression in vitro and in vivo implied that the oncolytic virus behaved similarly in both scenarios. Significant titers of viable virus were consistently isolated from tumors explanted from mice that had been injected with oncolytic measle viruses. We observed a weaker but positive in vivo relationship between radioisotope uptake and the viable virus titer recovered from tumors; this was likely due to anisotropies in the viral distribution in vivo These data suggest that methods that enable quantitation of in vivo anisotropies are required for continuing development of oncolytic virotherapy.Significance: These findings address a fundamental gap in our knowledge of oncolytic virotherapy by presenting technology that gives insight into the behavior of oncolytic viruses in vivo Cancer Res; 78(20); 5992-6000. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30115692      PMCID: PMC6191353          DOI: 10.1158/0008-5472.CAN-18-0447

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Authors:  D Kirn; R L Martuza; J Zwiebel
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Authors:  Karishma Rajani; Christopher Parrish; Timothy Kottke; Jill Thompson; Shane Zaidi; Liz Ilett; Kevin G Shim; Rosa-Maria Diaz; Hardev Pandha; Kevin Harrington; Matt Coffey; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

Review 3.  Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.

Authors:  Claud Grigg; Zoë Blake; Robyn Gartrell; Adrian Sacher; Bret Taback; Yvonne Saenger
Journal:  Semin Oncol       Date:  2016-10-27       Impact factor: 4.929

4.  Transcriptional map of the measles virus genome.

Authors:  P C Dowling; B M Blumberg; J Menonna; J E Adamus; P Cook; J C Crowley; D Kolakofsky; S D Cook
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

5.  Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer.

Authors:  Alan R Penheiter; Troy R Wegman; Kelly L Classic; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

6.  Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography.

Authors:  Alan R Penheiter; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

Review 7.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

8.  Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.

Authors:  K-W Peng; E M Hadac; B D Anderson; R Myers; M Harvey; S M Greiner; D Soeffker; M J Federspiel; S J Russell
Journal:  Cancer Gene Ther       Date:  2006-03-10       Impact factor: 5.987

9.  Altered ratios of measles virus transcripts in diseased human brains.

Authors:  R Cattaneo; G Rebmann; K Baczko; V ter Meulen; M A Billeter
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

10.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Authors:  David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

View more
  2 in total

1.  MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.

Authors:  Hans Martin Singh; Mathias Felix Leber; Sascha Bossow; Christine E Engeland; Jan Dessila; Christian Grossardt; Karim Zaoui; John C Bell; Dirk Jäger; Christof von Kalle; Guy Ungerechts
Journal:  Mol Ther Oncolytics       Date:  2021-05-05       Impact factor: 7.200

Review 2.  Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?

Authors:  Mohsen Keshavarz; Ailar Sabbaghi; Seyed Mohammad Miri; Abolhasan Rezaeyan; Yaser Arjeini; Amir Ghaemi
Journal:  Cancer Cell Int       Date:  2020-04-23       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.